Base Metals Investing Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
Base Metals Investing Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
Base Metals Investing Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
Base Metals Investing Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
Base Metals Investing Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Base Metals Investing Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Base Metals Investing Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Base Metals Investing Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint
Apollo Silver Announces Correction to Warrant Terms of $25 Million Strategic Investment by Eric Sprott and Jupiter Asset Management
